OV329 Therapy for Refractory CDKL5 Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapies to treat CDKL5 disorder, a severe X-linked genetic seizure disorder with early onset and refractory seizures, as current antiepileptic drugs provide inadequate seizure control and no approved drugs are available.
Innovation Solution
Administering (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or its pharmaceutically acceptable salt to a subject in need thereof, either alone or in combination with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof, to treat CDKL5 disorder, including before the onset of clinical seizures to reduce or prevent symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple antiepileptic drugs are used to treat CDKL5 disorder, then seizure control may be improved, but treatment complexity and side effects increase
Solution Approach 1:
The patent introduces a novel chemical compound with a specific molecular structure (cyclopentane ring with amino group, difluoromethylenyl group, and carboxylic acid group) that represents a parameter change in drug chemistry. This new chemical parameter aims to achieve better seizure control while potentially reducing the need for multiple drugs and their associated complexities
Solution Approach 2:
The patent focuses on a single specific enantiomer (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid rather than using broad-spectrum antiepileptic drugs. This segmentation approach targets the specific CDKL5 disorder mechanism with a precisely designed molecular structure, potentially avoiding the need for multiple different drug mechanisms
2Device complexity
If a single antiepileptic drug is used to treat CDKL5 disorder, then treatment simplicity is maintained, but seizure control is inadequate
Solution Approach 1:
The patent employs a chemically modified structure with specific parameters: a cyclopent-1-ene ring system, an amino group at position 3, a difluoromethylenyl group at position 4, and a carboxylic acid at position 1. These parameter changes in molecular structure are designed to achieve high efficacy against CDKL5-related seizures while maintaining single-drug treatment simplicity
Solution Approach 2:
The patent is inspired by the structure of vigabatrin (a known antiepileptic drug) but creates a novel copy with improved properties. The new compound copies the general approach of GABA-related therapy but uses a different chemical scaffold (cyclopentene vs. GABA structure) to achieve better efficacy with simpler treatment
3Reliability
If vigabatrin is used to treat CDKL5 disorder, then some seizure control is achieved, but efficacy is insufficient for many patients
Solution Approach 1:
The patent makes specific parameter changes to the vigabatrin-inspired structure by introducing a cyclopent-1-ene ring system with fluorine atoms and an amino group in a specific configuration. These parameter changes are designed to enhance the drug's ability to inhibit GABA transaminase and improve seizure control efficacy beyond what vigabatrin achieves
Solution Approach 2:
The patent creates a composite molecular structure that combines elements of known effective drugs (vigabatrin's mechanism of action) with novel chemical features (the difluoromethylenyl-cyclopentene scaffold). This composite approach aims to achieve superior efficacy by merging proven therapeutic mechanisms with innovative chemical structures
Data Source
AI summary
Methods of treating a seizure disorder with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of a seizure disorder. Methods of treating Prader-Willi syndrome with (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid, or (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid (KT-II-115), or a pharmaceutically acceptable salt of any of the preceding, are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of Prader-Willi syndrome.